Public Sector Pension Investment Board Has $7.20 Million Stock Holdings in Supernus Pharmaceuticals, Inc. $SUPN

Key Points

• Public Sector Pension Investment Board increased its holdings in Supernus Pharmaceuticals by 59.7%, now owning approximately 0.39% of the company worth $7.2 million.
• CEO Jack A. Khattar sold 140,000 shares for about $5.9 million, reducing his ownership stake to 1,030,183 shares valued at approximately $43.3 million.
• Analyst opinions are bullish, with Cantor Fitzgerald raising its price target from $42.00 to $46.00, calling the stock "overweight," and Wall Street Zen upgrading it from "hold" to "buy."

Public Sector Pension Investment Board increased its stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 59.7% during the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 219,731 shares of the specialty pharmaceutical company's stock after acquiring an additional 82,167 shares during the period. Public Sector Pension Investment Board owned about 0.39% of Supernus Pharmaceuticals worth $7,196,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently bought and sold shares of the stock. Nuveen LLC bought a new stake in shares of Supernus Pharmaceuticals during the 1st quarter worth approximately $4,393,000. Invesco Ltd. lifted its stake in Supernus Pharmaceuticals by 4.4% in the first quarter. Invesco Ltd. now owns 530,631 shares of the specialty pharmaceutical company's stock valued at $17,378,000 after acquiring an additional 22,562 shares during the last quarter. PNC Financial Services Group Inc. lifted its stake in Supernus Pharmaceuticals by 4.7% in the 1st quarter. PNC Financial Services Group Inc. now owns 16,097 shares of the specialty pharmaceutical company's stock valued at $527,000 after purchasing an additional 726 shares during the last quarter. Commerce Bank lifted its position in shares of Supernus Pharmaceuticals by 12.9% in the first quarter. Commerce Bank now owns 15,025 shares of the specialty pharmaceutical company's stock valued at $492,000 after buying an additional 1,720 shares during the last quarter. Finally, Jefferies Financial Group Inc. boosted its stake in shares of Supernus Pharmaceuticals by 230.5% during the 1st quarter. Jefferies Financial Group Inc. now owns 81,313 shares of the specialty pharmaceutical company's stock worth $2,663,000 after acquiring an additional 56,713 shares during the period.

Supernus Pharmaceuticals Stock Down 0.5%

NASDAQ SUPN traded down $0.2050 on Tuesday, hitting $42.7850. The company's stock had a trading volume of 161,926 shares, compared to its average volume of 635,533. The firm has a market cap of $2.40 billion, a PE ratio of 37.20 and a beta of 0.74. Supernus Pharmaceuticals, Inc. has a 1-year low of $29.16 and a 1-year high of $43.73. The company's 50-day moving average is $34.57 and its 200 day moving average is $33.53.

Insider Buying and Selling

In related news, Director Bethany Sensenig sold 5,369 shares of the firm's stock in a transaction that occurred on Thursday, August 14th. The stock was sold at an average price of $42.25, for a total transaction of $226,840.25. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Jack A. Khattar sold 140,000 shares of the business's stock in a transaction that occurred on Wednesday, August 6th. The shares were sold at an average price of $42.02, for a total value of $5,882,800.00. Following the completion of the transaction, the chief executive officer directly owned 1,030,183 shares in the company, valued at approximately $43,288,289.66. This trade represents a 11.96% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 152,826 shares of company stock valued at $6,424,773 over the last quarter. Insiders own 8.80% of the company's stock.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on the company. Wall Street Zen raised Supernus Pharmaceuticals from a "hold" rating to a "buy" rating in a report on Saturday, August 2nd. Cantor Fitzgerald raised their target price on shares of Supernus Pharmaceuticals from $42.00 to $46.00 and gave the stock an "overweight" rating in a research note on Wednesday, August 6th. Two research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $41.00.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.